Previous Close | 0.1550 |
Open | 0.1600 |
Bid | 0.1500 x 0 |
Ask | 0.1600 x 0 |
Day's Range | 0.1600 - 0.1600 |
52 Week Range | 0.0600 - 0.1700 |
Volume | |
Avg. Volume | 25,168 |
Market Cap | 17.897M |
Beta (5Y Monthly) | 0.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0300 |
Earnings Date | Dec 12, 2024 - Dec 16, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
EL CAJON, Calif., November 01, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and Quip Laboratories, Inc. ("Quip Labs"), have entered into a multi-year distribution agreement for the purchase and selling of SDC products under special terms and conditions.
EL CAJON, Calif., October 29, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2024.